Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

A successful acquisition strategy goes beyond the highest bid. It involves 'thinking like the molecule'—evaluating which buyer has the specific expertise, capabilities, and cultural alignment to best steward the asset's development. This reframes M&A from a financial transaction to a decision about the asset's future.

Major firms like Merck employ varied deal structures to build pipelines. Merck's $6.7 billion all-upfront acquisition of Terns for a Phase 1-2 asset contrasts with its Quotient collaboration, which has a small $20 million upfront but $2.2 billion in discovery-stage milestones. This highlights a flexible approach to risk and reward.

The M&A landscape is evolving as a new tier of large, but not Big Pharma-sized, biotechs are now executing their own billion-dollar acquisitions. Companies like Neurocrine, BioMarin, and Genmab are creating a new class of strategic buyers, diversifying exit opportunities for smaller biotech firms.

The M&A landscape is no longer dominated solely by big pharma. Mid-sized pharmas and large biotechs are emerging as aggressive acquirers. One global head of BD at a mid-sized firm noted they won a recent billion-dollar deal by moving from data room to offer in just three weeks, signaling a new competitive speed.

As large pharmaceutical companies shift focus to acquiring clinically validated assets, a gap has emerged in early-stage development. Smaller and mid-sized pharmas, unable to compete on price for late-stage assets, are now incentivized to take on more risk and partner earlier, driving innovation.

With patent cliffs looming and mature assets acquired, large pharmaceutical companies are increasingly paying billion-dollar prices for early-stage and even preclinical companies. This marks a significant strategic shift in M&A towards accepting higher risk for earlier innovation.

Deals like Neurocrin buying Soleno and Servier buying Day One illustrate a trend of mid-sized drug makers becoming significant buyers. This expands the pool of potential bidders beyond just large-cap pharma, creating more competitive M&A processes that can benefit selling companies and their investors.

The M&A landscape is evolving beyond Big Pharma's patent cliff-driven acquisitions. Mid-to-large biotechs like BioMarin, Insight, and Ionis are now positioned as buyers, creating a richer, more diverse deal-making ecosystem.